[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc (RLAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,691,783
  • Shares Outstanding, K 191,586
  • Annual Sales, $ 15,360 K
  • Annual Income, $ -276,480 K
  • EBIT $ -296 M
  • EBITDA $ -296 M
  • 60-Month Beta 1.74
  • Price/Sales 173.43
  • Price/Cash Flow N/A
  • Price/Book 4.14

Options Overview Details

View History
  • Implied Volatility 161.27% (+53.78%)
  • Historical Volatility 65.05%
  • IV Percentile 26%
  • IV Rank 12.99%
  • IV High 759.75% on 09/12/25
  • IV Low 71.91% on 05/20/26
  • Expected Move (DTE 17) 2.22 (15.79%)
  • Put/Call Vol Ratio 7.96
  • Today's Volume 3,558
  • Volume Avg (30-Day) 2,538
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 54,254
  • Open Int (30-Day) 37,398
  • Expected Range 11.83 to 16.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.42
  • Number of Estimates 5
  • High Estimate $-0.37
  • Low Estimate $-0.45
  • Prior Year $-0.41
  • Growth Rate Est. (year over year) -2.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.62 +20.91%
on 05/20/26
15.45 -9.06%
on 05/21/26
+1.48 (+11.77%)
since 04/29/26
3-Month
9.06 +55.08%
on 03/06/26
17.32 -18.88%
on 04/17/26
+3.79 (+36.94%)
since 02/27/26
52-Week
2.91 +382.82%
on 05/29/25
17.32 -18.88%
on 04/17/26
+11.10 (+376.27%)
since 05/28/25

Most Recent Stories

More News
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 14.05 (+1.08%)
Relay Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 14.05 (+1.08%)
Relay Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 14.05 (+1.08%)
Rising Bond Yields Weigh on Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -0.68%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.34%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.95%. June E-mini S&P futures...

ALK : 46.02 (-1.22%)
SNDK : 1,694.98 (+3.25%)
HL : 17.77 (+1.02%)
CDE : 19.32 (+3.93%)
ADI : 413.85 (-1.23%)
STUB : 9.86 (+0.61%)
CRWV : 109.53 (+2.50%)
STX : 879.80 (-0.10%)
WDC : 531.21 (+0.01%)
AMD : 516.10 (-0.38%)
SCCO : 191.30 (-1.84%)
SPY : 756.48 (+0.25%)
Stocks Pressured by Tech Weakness and Rising Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down -0.35%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.45%. June E-mini S&P futures...

ALK : 46.02 (-1.22%)
ADI : 413.85 (-1.23%)
STUB : 9.86 (+0.61%)
CRWV : 109.53 (+2.50%)
STX : 879.80 (-0.10%)
WDC : 531.21 (+0.01%)
AMD : 516.10 (-0.38%)
SPY : 756.48 (+0.25%)
ADSK : 231.31 (-4.00%)
AAL : 14.64 (-0.07%)
QQQ : 738.31 (+0.37%)
TOL : 138.54 (+0.29%)
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported...

RLAY : 14.05 (+1.08%)
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

FDA Breakthrough Therapy designation granted to  zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib...

RLAY : 14.05 (+1.08%)
Relay Therapeutics Reports While the Market Decides What Zovegalisib Really Means

Barchart Research What to Expect from RLAY Earnings RLAY Generated May 4, 2026 Current Price $13.09 EPS Estimate $$-0.35 Consensus Rating Strong Buy Average Move 6.98% Relay Therapeutics Reports While...

RLAY : 14.05 (+1.08%)
Relay Therapeutics Reports While Street Waits for Vascular Anomaly Data to Materialize

Barchart Research What to Expect from RLAY Earnings RLAY Generated May 1, 2026 Current Price $12.72 EPS Estimate $$-0.35 Consensus Rating Strong Buy Average Move 6.98% Relay Therapeutics Reports While...

RLAY : 14.05 (+1.08%)
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 14.05 (+1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 15.20
2nd Resistance Point 14.79
1st Resistance Point 14.42
Last Price 14.05
1st Support Level 13.64
2nd Support Level 13.23
3rd Support Level 12.86

See More

52-Week High 17.32
Last Price 14.05
Fibonacci 61.8% 11.82
Fibonacci 50% 10.11
Fibonacci 38.2% 8.41
52-Week Low 2.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.